Clinical Trial Design Poster NG-350A (FORTITUDE) ASCO 2019

A multicenter, open-label, first in human study of a vector expressing and agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors.

Click here for the Study Design Poster